A Phase 2 clinical trial testing the experimental oral therapy S-606001 as an add-on treatment for adults with late-onset Pompe disease (LOPD) has begun enrolling patients, according to an announcement from the trial’s sponsor, Shionogi. “This is an important milestone for Shionogi, as we continue to expand our…
S-606001
Recent Posts
- Parenting a child with Pompe comes with worries about an uncertain future
- High antibodies limit enzyme therapy in infantile Pompe, study finds
- Our family’s experience with Pompe disease is just one of many
- Use of methotrexate may make Pompe treatment more effective, per study
- 5 years strong: Combo LOPD therapy preserves walking and lung function